ETF Holdings Breakdown of DAWN

Stock NameDay One Biopharmaceuticals Inc
TickerDAWN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS23954D1090

News associated with DAWN

Analysts Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Price Target at $30.57
Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) have been given a consensus recommendation of “Buy” by the eight analysts that are covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 […] - 2025-06-19 05:46:56
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 15.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 75,579 shares of the company’s stock after buying […] - 2025-06-11 08:14:48
Two Sigma Investments LP Lowers Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Two Sigma Investments LP lessened its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 33.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 271,776 shares of the company’s stock after selling 135,725 shares during the quarter. Two Sigma […] - 2025-05-30 07:51:01
Deutsche Bank AG Buys 35,460 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Deutsche Bank AG raised its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 11.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 358,920 shares of the company’s stock after buying an additional 35,460 shares during the […] - 2025-05-20 08:12:56
Mariner LLC Sells 10,376 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Mariner LLC lessened its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 47.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 11,669 shares of the company’s stock after selling 10,376 shares during the period. Mariner LLC’s holdings in Day One Biopharmaceuticals were worth $148,000 as of its most recent filing with […] - 2025-05-08 07:40:46
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up Following Earnings Beat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $6.99, but opened at $7.52. Day One Biopharmaceuticals shares last traded at $6.64, with a volume of 935,489 shares trading hands. The company reported ($0.35) earnings […] - 2025-05-08 06:12:49
Hsbc Holdings PLC Makes New Investment in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Hsbc Holdings PLC acquired a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 38,583 shares of the company’s stock, valued at approximately $481,000. Several other hedge funds also […] - 2025-05-07 07:56:57
Wells Fargo & Company MN Sells 4,744 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Wells Fargo & Company MN cut its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 8.4% during the 4th quarter, Holdings Channel reports. The firm owned 51,735 shares of the company’s stock after selling 4,744 shares during the period. Wells Fargo & Company MN’s holdings in Day One Biopharmaceuticals were […] - 2025-05-02 07:24:48
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $32.29 Average Target Price from Analysts
Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) have been given an average rating of “Buy” by the eight analysts that are currently covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average […] - 2025-04-30 05:34:47
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Acquired by Fmr LLC
Fmr LLC increased its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 73.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,887,467 shares of the company’s stock after purchasing an additional 5,475,087 shares […] - 2025-04-14 08:15:07
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Corebridge Financial Inc.
Corebridge Financial Inc. reduced its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 7.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 25,805 shares of the company’s stock after selling 1,948 shares during the quarter. Corebridge Financial Inc.’s holdings in Day […] - 2025-04-11 08:40:56
Wellington Management Group LLP Grows Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Wellington Management Group LLP raised its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 1.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 731,303 shares of the company’s stock after purchasing an additional 9,722 shares during the quarter. Wellington Management […] - 2025-04-10 09:06:51
Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Cut to $27.00 by Analysts at The Goldman Sachs Group
Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) had its price objective trimmed by The Goldman Sachs Group from $39.00 to $27.00 in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other brokerages have also issued reports on DAWN. JPMorgan Chase & Co. dropped their […] - 2025-03-26 06:38:43
Charles Schwab Investment Management Inc. Raises Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)
Charles Schwab Investment Management Inc. boosted its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) by 5.5% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 535,501 shares of the company’s stock after buying an additional 28,053 shares during the period. Charles Schwab Investment Management Inc.’s […] - 2025-03-25 07:13:03
Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Lowered to $34.00 at JPMorgan Chase & Co.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) had its target price dropped by JPMorgan Chase & Co. from $39.00 to $34.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 273.63% from the company’s current […] - 2025-03-07 06:50:44
Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year Low Following Weak Earnings
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) hit a new 52-week low on Wednesday after the company announced weaker than expected quarterly earnings. The stock traded as low as $10.06 and last traded at $10.54, with a volume of 436845 shares. The stock had previously closed at $11.82. The company reported ($0.69) earnings […] - 2025-02-27 09:08:59
Day One Biopharmaceuticals (NASDAQ:DAWN) Given New $43.00 Price Target at The Goldman Sachs Group
Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) had its price objective decreased by The Goldman Sachs Group from $48.00 to $43.00 in a research note released on Monday morning,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock. Several other analysts have also issued reports on DAWN. Needham & Company LLC […] - 2025-02-11 08:28:49

DAWN institutional holdings

The following institutional investment holdings of DAWN have been identified

Date ETF ISIN/Name Num Shares Book value
2025-06-26 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 12,140USD 78,667
2025-06-26 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 48,816USD 316,328
2025-06-26 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 48,816USD 316,328
2024-11-12 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 329USD 5,146
2025-06-26 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 44,983USD 291,490
2025-06-26 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 95,844USD 621,069
Total =250,928 USD 1,629,028
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.